A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study
| Autor: | Youling Gong, Zhi-gang Yang, Yuan Li, Tong Pang, Wen-lei Qian, Wei-feng Yan, Xin Tang |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Lung Neoplasms T790M Carcinoma Non-Small-Cell Lung Internal medicine Humans Medicine Osimertinib Lung cancer Protein Kinase Inhibitors Aniline Compounds Hematology Performance status business.industry Proportional hazards model Standard treatment Bone metastasis General Medicine Prognosis medicine.disease respiratory tract diseases ErbB Receptors Mutation business |
| Zdroj: | Journal of Cancer Research and Clinical Oncology. 148:2475-2486 |
| ISSN: | 1432-1335 0171-5216 |
| Popis: | Osimertinib is the standard treatment for advanced non-small cell lung cancer (NSCLC) patients with T790M mutation after the failure of first-/second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). We comprehensively analyzed factors that affect the therapeutic efficacy of the osimertinib treatment in NSCLC patients. 351 NSCLC patients with T790M mutation receiving osimertinib treatment were included. We investigated the value of different factors in predicting the clinical outcomes of the osimertinib therapy, including progression-free survival (PFS), overall survival (OS) and objective response rate (ORR). Logistic and COX regression were used to identify prognosticators. In osimertinib therapy, EGFR mutation status (19Del/L858R) at initial diagnosis and the therapeutic choice of prior EGFR-TKI agent was not associated with patients’ prognosis. Notably, the PFS of the prior EGFR-TKI was independently related to ORR (OR, 95% CI 0.98, 0.96–1.00, p = 0.030), PFS (HR, 95% CI 0.98, 0.97–1.00, p = 0.009) and OS (HR, 95% CI 0.96, 0.93–0.98, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink